David McIntosh: Plasma Derived Medicines and the Global Access Gap
David McIntosh, Founder and Chair of United Plasma Action, shared a post by Plasma Protein Therapeutics Association (PPTA) on LinkedIn:
“I repost this in a worried state of mind. I feel that it needs a good deal of further explanation and I feel a duty to explain why.
All of us who are involved in the field of Plasma Derived Medicines (PDMPs) will surely welcome the work of the team at International Plasma Awareness Week.
There’s no doubt about how immensely valuable these treatments are for many patients in those parts of the World where they’re available.
However
The most important item in need of increased awareness is the desperately sad fact that some 80 percent of all the rare disease sufferers in this World have little or no access to PDMPs at all.
The consequent unnecessary suffering and avoidable death, globally, is quite breath-taking.
It seems VERY sad therefore, on pursuing the awareness raising link offered us in the post below, to find mention only of Europe and the USA with no apparent awareness of the plight of the global majority of people and places affected.
Most patients in Europe and North America, most of the time, are pretty well taken care of. In those places, PDMPs are already relatively plentiful.
However, this is very far from true in Low and Middle Income Countries where access to PDMPs is either completely absent or severly limited and where awareness raising and remedial action is most desperately needed.
Do those countries, those patients, not come within the scope of the IPAW initiative?
Their exclusion from the headline IPAW information site would seem to imply just that.
There must surely either be a bad mistake in the site design here, or a fundamental strategic error in the design of the whole initiative.
Surely
One does wonder which is in fact the case.”
Plasma Protein Therapeutics Association (PPTA) shared a post on LinkedIn:
“Save the date for IPAW!
Plasma donors make a lifesaving difference for families with loved ones who need plasma derived medicines.
Learn more about plasma donation and how you can get involved at plasmaweek.org.”

Stay updated with Hemostasis Today.
-
Sep 26, 2026, 06:49Heghine Khachatryan: Navigating the Complexities of Pediatric VTE
-
Sep 26, 2026, 06:44Emmanuel J Favaloro: A Century of von Willebrand Disease 2026 Virtual Issue
-
Sep 26, 2026, 05:12Saja Al-Zamili: Dual Antithrombotic Therapy After Ischemic Stroke in Atrial Fibrillation – A Meta-Analysis
-
Sep 26, 2026, 04:58Angelo Cascio Rizzo: Ischemic Stroke Phenotyping in ESUS – Insights from a Real-World Cohort
-
Sep 26, 2026, 03:11Alice Mihai: One Blood Donation, Three Lives Touched
-
Sep 26, 2026, 03:01Jensa Morris: Anticoagulation in Thrombocytopenia and Cancer-Associated Thrombosis
-
Sep 26, 2026, 02:37Alireza Arzhangzadeh: Antithrombotic Strategies in Coronary Artery Aneurysm, Ectasia, and Slow Flow
-
Sep 26, 2026, 02:15Sherif Mahmoud: Updated Guideline for Antithrombotic-Associated Intracranial Hemorrhage
-
Sep 25, 2026, 20:01Anand Gupta: Timing of DOAC Initiation in Newly Diagnosed Atrial Fibrillation